Stellantis (BIT:STLAM) Stock Price Sinks After Q3 Earnings Loss

Simply Wall St · 2d ago

Stellantis just dropped Q3 2026 earnings and the stock closed at €4.22, capping a choppy three months where the share price has fallen about 15%. The headline is simple: revenue held at €37.6b while the group swung to a net loss of €470m and earnings per share slipped to a loss of €0.18.

The market is reacting to pain on the income statement. The more interesting story sits in the small but clear uplift in adjusted operating income and the early cost cuts that are starting to move margins, even as sentiment stays firmly in the penalty box.

Love the early Stellantis margin progress but worried about a headline net loss and choppy sentiment? Screen for sturdier setups with our list of solid balance sheet and fundamentals stocks (207 results)

Q3 2026 Earnings Summary

  • Revenue (Q3 2026 vs Q3 2025): €37.6b vs. €39.6b (roughly flat top line with a modest decline)
  • Net Loss (Q3 2026 vs Q3 2025): loss of €470m vs. loss of €10.1b (loss narrowed sharply year on year)
  • Basic EPS (Q3 2026 vs Q3 2025): loss of €0.18 per share vs. loss of €3.48 per share (per share loss reduced materially)
  • Adjusted Operating Income Margin (Q3 2026 vs Q3 2025): 0.7% vs. roughly 0.2% (margin moved higher, supported by cost cuts)

Prefer clean visuals instead of another wall of Stellantis earnings tables and raw figures? See the full picture of the stock, covering valuation and income statement through to ownership, balance sheet, dividends and price chart history, in our company report for Stellantis.

BIT:STLAM Trailing 12-Month Earnings & Revenue History as at Oct 2026
BIT:STLAM Trailing 12-Month Earnings & Revenue History as at Oct 2026

Stellantis Cost Story: Early Proof, Not Theory

The bullish pitch says Stellantis wins if cost discipline, not just volume, does the heavy lifting on profits.

"The main factor that has to go right is execution on the Value Creation Program cost savings and product upgrades so that North America and the captive finance arm deliver the targeted profit and cash flow uplift despite tariff, raw material and European pricing headwinds."

Q3 gives real, if early, evidence. Adjusted operating income rose while revenue stayed roughly flat and shipments dipped. That points directly to savings and mix, not sales growth. Management now expects to exceed the 40% Value Creation Program milestone by year end, with more than €2.4b run rate savings entering 2027. The cost thesis is starting to line up with the narrative rather than sitting on a slide.

One Narrative disagrees with today's price. → See where this Narrative says Stellantis should trade.

Stellantis Bear Case: Tariffs, Inventory And Execution Scorecard

Bearish research argues Stellantis will struggle to turn cost cuts into real profit while tariffs and weak regions soak up the gains.

"While management plans to reduce European manufacturing capacity by more than 800,000 units without plant closures and aims to raise utilization from about 60% to about 80% by 2030, the continuing AOI loss in Enlarged Europe of €94 million in Q2 2026, together with a 20% year over year rise in total inventory to 1.4 million units, points to a risk that fixed costs remain under absorbed, which would keep regional and possibly group earnings below the targeted 7% AOI margin."

Q3 confirms that concern. Inventories still sit at 1.4 million units and industrial free cash flow remains a €4.0 billion outflow, even as group AOI edges to 0.7%. North America pricing and cost cuts help, yet the global net loss and heavy working capital drag show the utilization and inventory milestones are not yet met.

Hunt For Quiet Mispricing

Stellantis shows how a cleaner income story can still appear beside a net loss and a soft share price. The real opportunity is finding stocks that could be undervalued before the crowd catches up.

  • Company 1 - 25% below our estimate - focuses on custom chips and connectivity gear that large cloud customers rely on for high performance infrastructure.
  • Company 2 - 22% below our estimate - shifts its sealing portfolio toward higher value healthcare components as capsule capacity, integrations and footprint changes come together.
  • Company 3 - 43% below our estimate - converts a record backlog of technology heavy data center and modular building projects into long multi-year installation and service work.

Three companies from the same screener. Open every one of the 191 undervalued companies on it →